Table 1.
population characteristics
| Characteristics | Number of patients | Percentage & range | P (Cox analysis for PFS) |
|---|---|---|---|
| Gender | 56 | 100% | 0.050 |
| Male | 33 | 58.9% | |
| Female | 23 | 41.1% | |
| Age at diagnosis | 0.982 | ||
| Median (min–max) (year) | 24.5 | 9–63 | |
| Pathological diagnosis | 56 | 100% | 0.087 |
| Osteosarcoma | 22 | 39.3% | |
| Ewing sarcoma | 10 | 17.9% | |
| Synovial sarcoma | 6 | 10.7% | |
| MPNSTa | 3 | 5.4% | |
| Epithelioid sarcoma | 2 | 3.6% | |
| UPSb | 4 | 7.1% | |
| Fibrosarcoma | 1 | 1.8% | |
| Chondrosarcoma | 3 | 5.4% | |
| ASPSc | 3 | 5.4% | |
| Othersd | 2 | 3.6% | |
| Tumor grade | |||
| Grade III | 56 | 100% | |
| Location of primary disease | 56 | 100% | 0.374 |
| Axial skeleton | 17 | 30.3% | |
| Extremities | 37 | 66.1% | |
| Otherse | 2 | 3.6% | |
| Localization of relapse | 56 | 100% | 0.541 |
| Localized | 3 | 5.6% | |
| Metastatic | 41 | 73.2% | |
| Both | 12 | 21.4% | |
| Type of metastasis | 53 | 94.6% | 0.197 |
| Lung only | 40 | 71.4% | |
| Bone only | 3 | 5.4% | |
| Both | 5 | 8.9% | |
| Othere | 5 | 8.9% | |
| Time interval from initial chemotherapy to using apatinib | 0.584 | ||
| Median (min–max) (month) | 15.6 | 0.9–373.9 | |
| Number of previous treatment lines | 56 | 100% | 0.231 |
| 0 | 5 | 8.9% | |
| 1 | 37 | 66.1% | |
| 2 | 12 | 21.4% | |
| > 2 | 2 | 3.6% | |
| Follow-up time | |||
| Median (min–max) (month) | 6.0 | 0.7–18.0 | |
aMPNST: malignant peripheral nerve sheath tumor
bUPS: undifferentiated pleomorphic sarcoma
cASPS: alveolar soft part sarcoma
dothers including extraskeletal osteosarcoma one case and mucinous type liposarcoma one case
eothers including mediastinum and soft tissue of the backside
fothers including lymph nodes metastasis or intravenous tumor emboli as well as liver, brain metastasis